The efficacy of CD19-CAR-T therapy on B-ALL was positively correlated with the abundance of CAR and immune cell subpopulations, e.g., CD8<sup>+</sup> T cells and natural killer (NK) cells, in the bone marrow. The gene discussed is CD8A; the disease is acute lymphoblastic leukemia.